enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Jan 31, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Dec 31, 2022	Oct 31, 2022
Cash & Equivalents	36.61	50.15	173	81.52	20.43	20.43
Short-Term Investments	239.41	143.66	65.4	0.08	0.07	0.07
Cash & Short-Term Investments	276.02	193.82	238.4	81.6	20.51	20.51
Cash Growth	29.05%	-18.70%	192.17%	297.88%	-	-
Other Receivables	1.2	0.93	0.33	2.34	1.34	1.34
Total Trade Receivables	1.2	0.93	0.33	2.34	1.34	1.34
Other Current Assets	12	6.65	8.63	1.5	0.74	0.74
Total Current Assets	289.22	201.39	247.36	85.44	22.58	22.58
Net Property, Plant & Equipment	9.91	10.19	2.91	0.59	0.39	0.39
Long-Term Investments	36.6	8.52	59.53	-	-	-
Other Long-Term Assets	1.39	1.36	1.37	0.93	0.94	0.94
Total Assets	337.11	221.47	311.17	86.96	23.91	23.91
Accounts Payable	2.44	6.69	1.41	1.16	0.72	0.72
Accrued Expenses	19.67	15.28	12.13	3.54	3.12	3.12
Current Portion of Long-Term Debt	0.19	8	0.7	0.56	1.27	1.27
Current Portion of Leases	2.32	2.01	0.42	-	-	-
Total Current Liabilities	24.61	31.98	14.66	5.26	5.1	5.1
Long-Term Debt	24.74	15.32	22.47	9.22	27.05	27.05
Long-Term Leases	6.22	6.46	1.43	-	-	-
Other Long-Term Liabilities	-	-	-	-	15.25	15.25
Total Long-Term Liabilities	30.96	21.78	23.9	9.22	42.3	42.3
Total Liabilities	55.57	53.76	38.56	14.47	47.41	47.41
Common Stock	631.99	513.28	509.81	259.37	16.39	16.39
Additional Paid-in Capital	52.18	27.35	18.95	13.72	7.68	7.68
Accumulated Other Comprehensive Income	-0.84	-0.89	-1.42	-1.02	-1.02	-1.02
Retained Earnings	-401.78	-372.03	-254.73	-199.59	-99.67	-99.67
Total Common Shareholders' Equity	281.55	167.71	272.61	72.49	-76.61	-76.61
Minority Interest	-	-	-	-	53.12	53.12
Shareholders' Equity	281.55	167.71	272.61	72.49	-23.5	-23.5
Total Liabilities & Equity	337.11	221.47	311.17	86.96	23.91	23.91
Total Debt	33.46	31.8	25.02	9.78	28.32	28.32
Net Cash (Debt)	242.56	162.02	213.38	71.82	-7.81	-7.81
Net Cash Growth	49.71%	-24.07%	197.11%	-	-	-
Net Cash Per Share	4.39	3.17	5.65	103.69	-11.73	-11.92
Book Value	281.55	167.71	272.61	72.49	-76.61	-76.61
Book Value Per Share	5.10	3.28	7.22	104.66	-115.08	-116.94
Tangible Book Value	281.55	167.71	272.61	72.49	-76.61	-76.61
Tangible Book Value Per Share	5.10	3.28	7.22	104.66	-115.08	-116.94

Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q